# Merganser Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/merganser-biotech

- Industry: Pharmaceuticals
- Headquarters: US
- Total disclosed funding: $56M
- Latest round: Series A (Feb 19, 2015)
- Investors on record: 5

## About

Founded in 2011, Merganser Biotech, Inc. develops peptidyl therapeutics products and new treatments for diseases involving an overload in iron.

## Funding rounds

- Series A, Feb 19, 2015, $28M — Frazier Healthcare Partners, Novartis Venture Fund, Sutter Hill Ventures, OUP (Osage University Partners), BioAdvance
- Series A, Feb 1, 2015, $28M — Frazier Healthcare Partners, Novartis Venture Fund, Sutter Hill Ventures, BioAdvance
- Seed, Dec 9, 2011 — BioAdvance

## Investors

- BioAdvance (https://capitalatlas.ai/funds/bioadvance) — Seed, Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A